SLAM
KNSA icon

Swiss Life Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Swiss Life Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– – – 1215
2026
Q1 		– Sell
-4,894
Closed -$202K – 1569
2025
Q4 		$202K Buy
+4,894
New +$196K ﹤0.01% 1286

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Swiss Life Asset Management's KNSA Position: Q2 2026 in Review

Swiss Life Asset Management held its Kiniksa Pharmaceuticals (KNSA) position steady in Q2 2026 at 0 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #1215.

Swiss Life Asset Management first reported a position in KNSA in Q4 2025 and has held it in 1 quarter since. The position peaked at $202K in Q4 2025. 175 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Swiss Life Asset Management held 0 shares of Kiniksa Pharmaceuticals worth $324K as of Q2 2026.
  • Swiss Life Asset Management left its Kiniksa Pharmaceuticals share count unchanged in Q2 2026.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1215 holding.
  • Swiss Life Asset Management first reported a position in Kiniksa Pharmaceuticals in Q4 2025 and has held it in 1 quarter since.
  • Swiss Life Asset Management's Kiniksa Pharmaceuticals position peaked at $202K in Q4 2025.
  • 175 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.